January 31, 2026 · Form 4 insider transaction
ABERNETHY MATT bought 2,437 shares of Neurocrine Biosciences, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as option exercise and disclosed on an SEC Form 4, filed 3 days after the transaction.
Includes an aggregate of 218 shares purchased on August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.